enGene Holdings Inc.

Equities

ENGN

CA29286M1059

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
12.57 ^USD	-2.26%		-4.34%	+36.19%

May. 15	EnGene Holdings Inc. Approves Board Appointments	CI
Apr. 22	Wells Fargo Starts enGene Holdings With Overweight Rating, $30 Price Target	MT

EnGene Holdings Inc. Announces Resignation of Jason Hanson as Chief Executive Officer

February 14, 2024 at 06:45 am EST

enGene Holdings Inc. announced that due to personal family and health reasons, Jason Hanson intends to resign from his role as chief executive officer upon the appointment of a successor CEO. The Board of Directors has initiated a search for his successor. Following the hiring of a new CEO, he will support the company and the new CEO as a strategic advisor.

Latest news about enGene Holdings Inc.

EnGene Holdings Inc. Approves Board Appointments	May. 15	CI
Wells Fargo Starts enGene Holdings With Overweight Rating, $30 Price Target	Apr. 22	MT
Guggenheim Starts enGene Holdings With Buy Rating, $34 Price Target	Apr. 15	MT
EnGene Holdings Inc. Appoints Raj Pruthi as SVP, Urologic Oncology and Clinical Development	Apr. 09	CI
UBS Initiates Coverage on enGene Holdings With Buy Rating, $37 Price Target	Mar. 28	MT
EnGene Holdings Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	Mar. 11	CI
Morgan Stanley Starts Coverage on Engene With Overweight Rating, $40 Price Target	Mar. 08	MT
Leerink Partners Starts enGene Holdings With Outperform Rating, $31 Price Target	Feb. 20	MT
EnGene Holdings Inc. announced that it has received CAD 200 million in funding from a group of investors	Feb. 19	CI
Top Midday Gainers	Feb. 14	MT
EnGene Holdings Inc. Announces Resignation of Jason Hanson as Member of the Board of Directors	Feb. 14	CI
EnGene Holdings Inc. Announces Resignation of Jason Hanson as Chief Executive Officer	Feb. 14	CI
EnGene Holdings Inc. announced that it expects to receive CAD 200 million in funding from a group of investors	Feb. 13	CI
EnGene Holdings Inc. Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary	Jan. 30	CI
EnGene Holdings Inc. Together with Its Subsidiaries, Engene Inc. and Engene USA, Inc. Enters into an Amended and Restated Loan and Security Agreement	Dec. 28	CI
EnGene Holdings Inc. Announces Expanded $50 Million Debt Facility with Hercules Capital	Dec. 22	CI
EnGene Holdings Inc. announced that it expects to receive $50 million in funding	Dec. 21	CI
EnGene Holdings Inc. Appoints Lota S. Zoth as Member of the Board of Directors and Audit Committee Chair	Dec. 20	CI
EnGene Holdings Inc Appoints Ryan Daws as Head of Business Development	Nov. 29	CI
EnGene Holdings Inc. Appoints Ryan Daws as Chief Financial Officer	Nov. 29	CI

Chart enGene Holdings Inc.

Duration

Period

More charts

Company Profile

enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Companyâs proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Companyâs DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.

Sector

Biotechnology & Medical Research

Calendar

2024-06-05 - Jefferies Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.5 USD

Average target price

34.4 USD

Spread / Average Target

+227.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENGENE HOLDINGS INC.	+36.19%	463M
MODERNA, INC.	+43.36%	58.06B
IQVIA HOLDINGS INC.	-5.31%	40.53B
LONZA GROUP AG	+37.52%	38.99B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.7B
CELLTRION, INC.	-12.56%	26.56B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.98B
BIO-TECHNE CORPORATION	+0.04%	12.17B
UNITED THERAPEUTICS CORPORATION	+25.12%	12B
MEDPACE HOLDINGS, INC.	+26.04%	11.92B

Other Biotechnology & Medical Research